How effective is Cabozantinib
Cabozantinib, as a multi-target tyrosine kinase inhibitor, has shown significant efficacy in various cancer treatments, mainly manifested in prolonging progression free survival, controlling tumor growth, and improving patient prognosis.
1. Clinical efficacy data
(1) Thyroid medullary carcinoma: The median progression free survival was 11.2 months, significantly prolonged by 7.2 months compared to the placebo group.
(2) Renal cell carcinoma: The objective response rate of monotherapy is 17%, which increases to 48% when combined with nivolumab.
(3) Hepatocellular carcinoma: The median overall survival with second-line treatment is 10.2 months, which is 2.2 months longer than the control group.
2. Advantages of mechanism of action
(1) Broad spectrum inhibition: Simultaneously targeting 9 kinases such as MET and VEGFR, blocking tumor angiogenesis and metastasis.
(2) Synergistic effect: Combined with immunotherapy, it can improve the tumor microenvironment and enhance anti-tumor activity.
3. Factors affecting therapeutic efficacy
(1) Target expression: Patients with MET or RET gene abnormalities have a higher response rate.
(2) Medication plan: Combination therapy shows a significant improvement in efficacy compared to monotherapy.
(3) Tolerance: About 60% of patients require dose adjustment, which affects the sustained efficacy.
4. Special population effects
(1) Pediatric patients: Differentiated thyroid cancer patients over 12 years old show comparable efficacy to adults.
(2) Liver dysfunction: Moderate damage patients need to reduce dosage, otherwise it may affect the efficacy and safety.
Disclaimer：《How effective is Cabozantinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！